Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology

Rhea-AI Summary

Sunshine Biopharma (NASDAQ:SBFM) announced issuance of U.S. Patent 12,624,066 B2 covering proprietary small-molecule compounds for treatment of coronavirus infection. The patent protects PLpro enzyme inhibitors designed to block viral replication and immune suppression. Compounds are ready for GLP studies, the final step before entering clinical trials.

Positive

• U.S. Patent 12,624,066 B2 granted for coronavirus treatment technology
• Patent covers proprietary PLpro-targeting small-molecule inhibitors
• Compounds have advanced to GLP-study readiness, preceding clinical trials

Negative

• Therapeutic candidates have not yet entered clinical trials
• No regulatory approvals or commercialization timelines disclosed for the compounds

News Market Reaction – SBFM

-19.84%

23 alerts

-19.84% Session close to close

-20.0% Trough in 14 hr

$5.12M Market Cap

0.1x Rel. Volume

In the May 29 session, SBFM declined 19.84%, reflecting a significant negative market reaction. Argus tracked a trough of -20.0% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -19.8% in the session following this news. A negative reaction despite patent news...

Analysis

The stock dropped -19.8% in the session following this news. A negative reaction despite patent news would fit a pattern where Sunshine Biopharma’s shares often reflected financing overhang and prior reverse-split pressure. The stock recently fell 25.31% around a 1-for-10 reverse split and saw mixed responses to capital raises. With the price at $0.317 versus a $1.29 200-day MA, traders may have focused on balance sheet and dilution history over longer-term antiviral potential.

Key Figures

Coronavirus patent: U.S. Patent No. 12,624,066 B2

1 metrics

Coronavirus patent U.S. Patent No. 12,624,066 B2 Issued for compounds and methods for treatment of coronavirus infection

Historical Context

5 past events · Latest: May 28 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 28	Reverse stock split	Negative	-25.3%	1-for-10 reverse split to address Nasdaq minimum bid requirement.
May 21	Regulatory approval	Positive	+40.6%	Canadian regulatory approval for generic Amoxicillin with August 2026 launch target.
May 19	Offering closing	Negative	-8.2%	Closing of public offering raising about $6.0M with added warrant overhang.
May 18	Offering pricing	Negative	+79.5%	Pricing of $6.0M unit offering at $0.50 with Series C warrants attached.
Apr 06	Annual results	Neutral	+11.5%	Fiscal 2025 results: modest revenue growth, higher net loss, cost-cut plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often produced large one-day moves, with financings and corporate actions triggering both sharp rallies and selloffs.

Recent Company History

Over the last few months, Sunshine Biopharma combined capital raises, corporate actions, and operational milestones. A 1-for-10 reverse split announced on 2026-05-28 coincided with a -25.31% move. Earlier in May, a public offering priced at $0.50 per unit later closed with about $6.0 million gross proceeds, generating both a 79.51% surge and a separate -8.22% drop around related events. Regulatory approval for generic Amoxicillin on 2026-05-21 and fiscal 2025 revenue of $36.31 million each saw positive price reactions.

Key Terms

u.s. patent, small molecule inhibitors, plpro, glp studies, +1 more

5 terms

u.s. patent regulatory

"announced that the United States Patent and Trademark Office has issued U.S. Patent No."

A U.S. patent is a government-granted right that gives its holder exclusive control over making, using, selling or importing a specific invention inside the United States for a limited time. Think of it like owning the only key to a locked box or a secret recipe for a product. For investors, patents can create a legal barrier against competitors, boost potential sales or licensing income, and therefore increase a company’s value — but they also require time and money to obtain and defend, and their protection ends when they expire.

small molecule inhibitors medical

"The patent covers a series of small molecule inhibitors discovered and developed by Sunshine"

Small molecule inhibitors are compact chemical drugs designed to enter cells and block specific proteins or biological pathways that cause disease, acting like a tiny wrench that jams a particular gear inside a machine. For investors, they matter because their size often allows for pill forms, potentially lower manufacturing costs, clearer patent pathways, and broad market reach, while clinical trial results and safety profiles directly affect a drug developer’s valuation and commercial potential.

plpro medical

"These compounds target a critical viral enzyme (PLpro) responsible for suppression"

PLpro is an enzyme produced by certain viruses that acts like a pair of scissors to cut viral proteins into working pieces and also helps the virus hide from the body’s defenses. For investors, PLpro matters because drugs or tests that block or measure this enzyme can stop virus replication or improve treatments, so developments involving PLpro can affect the value and prospects of biotech companies developing antivirals.

glp studies regulatory

"The compounds covered under U.S. Patent 12,624,066 B2 are currently ready for GLP studies"

GLP studies are laboratory tests conducted under a standardized set of quality rules called Good Laboratory Practice, designed to ensure that preclinical safety and toxicology data are accurate, traceable and repeatable. For investors, GLP compliance matters because regulators rely on these trustworthy results when deciding whether a drug, medical device or chemical is safe enough to proceed to human trials or approval—similar to a third‑party inspection that verifies a product’s safety before it reaches consumers.

clinical trials medical

"GLP studies which is the step necessary to be completed before entering clinical trials."

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled "Compounds and Methods for Treatment of Coronavirus Infection." The newly granted patent protects Sunshine Biopharma's proprietary therapeutic compounds designed to inhibit coronavirus replication.

The patent covers a series of small molecule inhibitors discovered and developed by Sunshine Biopharma scientists during the COVID-19 pandemic. These compounds target a critical viral enzyme (PLpro) responsible for suppression of the human immune system, making Coronavirus infections life-threatening.

Coronaviruses are known for their high mutation rate, a biological characteristic that has already produced multiple variants of concern since 2020. Each new mutation has the potential to alter transmissibility, disease severity, or resistance to existing treatments and vaccines. Scientific experts worldwide continue to warn that Coronavirus remains one mutation away from triggering another global health crisis.

Sunshine Biopharma's patented technology is designed with this evolutionary reality in mind. By targeting a highly conserved viral function, the Company aims to develop antiviral candidates that remain effective even as the virus continues to mutate.

"The issuance of this patent is a major milestone for Sunshine Biopharma and a validation of our scientific strategy," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "Coronaviruses mutate rapidly, and the world cannot assume the threat has passed. Our goal is to advance therapies that can help address not only today's variants but also those that may emerge in the future."

The compounds covered under U.S. Patent 12,624,066 B2 are currently ready for GLP studies which is the step necessary to be completed before entering clinical trials. Sunshine Biopharma continues to invest in research aimed at developing robust solutions to current and future viral threats.

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

For more information, please contact:

Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com

SOURCE: Sunshine Biopharma Inc.

View the original press release on ACCESS Newswire

FAQ

What did Sunshine Biopharma (NASDAQ:SBFM) announce on May 29, 2026 about U.S. Patent 12,624,066 B2?

Sunshine Biopharma announced issuance of U.S. Patent 12,624,066 B2 for its coronavirus treatment technology. According to Sunshine Biopharma, the patent covers proprietary small-molecule compounds designed to inhibit coronavirus replication by targeting the PLpro viral enzyme involved in immune suppression.

How does Sunshine Biopharma's new coronavirus patent technology work against infection (SBFM)?

The patented technology targets the coronavirus PLpro enzyme to inhibit replication and immune suppression. According to Sunshine Biopharma, PLpro is a critical viral function, and inhibiting it may help maintain immune response and support development of antiviral candidates resilient to future coronavirus mutations.

What development stage are Sunshine Biopharma's patented coronavirus compounds at for SBFM investors?

Sunshine Biopharma states its patented coronavirus compounds are currently ready for GLP studies. According to Sunshine Biopharma, these GLP studies are the necessary step before entering clinical trials, marking an early but defined transition toward potential human testing of the antiviral candidates.

Why is the PLpro target important in Sunshine Biopharma's coronavirus strategy (NASDAQ:SBFM)?

PLpro is important because it helps coronavirus suppress the human immune system, worsening infection. According to Sunshine Biopharma, its PLpro-targeting compounds aim at a highly conserved viral function, which may help retain effectiveness even as new coronavirus variants and mutations emerge over time.

How could Sunshine Biopharma's U.S. Patent 12,624,066 B2 address future coronavirus variants for SBFM shareholders?

The patent supports development of antivirals designed to remain effective as the virus mutates. According to Sunshine Biopharma, focusing on a highly conserved PLpro function may help address both current variants and potential future strains that could impact global health and treatment needs.

Is Sunshine Biopharma's coronavirus treatment from patent 12,624,066 B2 in clinical use yet?

No, the coronavirus compounds are not yet in clinical trials or clinical use. According to Sunshine Biopharma, the molecules are ready for GLP studies, which must be completed before human trials can begin, so any therapeutic application remains at a preclinical development stage.